DCGI Approves Phase II/III Clinical Trial of COVAXIN in Age Group of 2 to 18 Years
New Delhi: The Drugs Controller General of India (DCGI) has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18…